CHF Solutions, Inc. (NASDAQ: CHFS) shares surged 14% after the company this morning said it has commenced the process of transitioning the manufacturing of the Aquadex FlexFlow System from an indirect subsidiary of Baxter International, Inc. (NYSE: BAX) to CHF Solutions’ facility in Eden Prairie, Minnesota. Last week, the company completed the transfer of the manufacturing assets that it acquired from Baxter as part of the Aquadex acquisition that was completed on August 5, 2016. The company expects to begin manufacturing its Aquadex FlexFlow system products in the fourth quarter of 2017. “Bringing the manufacturing of the Aquadex FlexFlow system products in-house will give us greater control and flexibility in managing our operations. Over time, we expect that this will result in improved gross margins as volumes and capacity utilization increases,” CHF Solutions chairman and CEO John Erb stated in the news release.
To view the full press release, visit: http://nnw.fm/MIm0J
About CHF Solutions
CHF Solutions, Inc. (NASDAQ: CHFS) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012. For more information, visit http://ir.sunshineheart.com.
More from CBDNewsBreaks
Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO
India Globalization Capital, Inc. (NYSE: IGC) Management Quoted in “HIGH TIMES” Article
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
